Comparing effect of intravenous parecoxib for acute pain management before and after incision in total abdominal hysterectomy

Status

Unknown

Phases

Phase 4

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230524003

Enrollment

Registered

2023-05-24

Start date

2023-05-14

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post operative acute pain management acute pain management in total abdominal hysterectomy

Interventions

The patient was received intravenous parecoxib 40 mg before the operation about 1 hour ,The patient was received intravenous parecoxib 40 mg after the operation about 2 hour

Active Comparator Drug,Active Comparator Drug

Eligibility

Sex/Gender

Female

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. 18-65 years old 2. total abdominal hysterectomy operation, midline incision 3. no underlyling disease eg. myocardial infarction, congestive heart failure, GI bleeding, stroke 4. no drug allergy to parecoxib, NSAIDs, sulfonamides, aspirin and bupivacaine 5. serum creatinine < 1.5 mg/dL 6. no hepatic failure(Child-Pugh Class C)

Exclusion criteria

Exclusion criteria: 1. withdrawal from this study 2. operation under general anesthesia

Design outcomes

Primary

Measure	Time frame
pain score 6, 12, 18, 24 hours after surgery visual analogue scale	—

Secondary

Measure	Time frame
tramadol consumption first 24 hours after surgery mg	—

Countries

Thailand

Contacts

Public ContactPenpak Jensarasart

Makarak Hospital

penpak_jen@hotmail.com0649359058

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026